<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01249521</url>
  </required_header>
  <id_info>
    <org_study_id>03501</org_study_id>
    <nct_id>NCT01249521</nct_id>
  </id_info>
  <brief_title>Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-na√Øve Metastatic Colorectal Cancer</brief_title>
  <acronym>Vengeance</acronym>
  <official_title>Open Label Phase II Study Evaluating the Combination of Bevacizumab and AMG386 Without Chemotherapy as First Line Treatment of Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austin Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Austin Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial investigating the effectiveness and safety of the combination of the&#xD;
      study drugs bevacizumab and AMG386 in patients with advanced (metastatic) chemotherapy-naive&#xD;
      bowel (colorectal) cancer. Chemotherapy has a significant impact in metastatic bowel cancer&#xD;
      in terms of maintenance of quality of life and extension of survival. However, ultimately&#xD;
      tumours will develop resistance to these agents and further treatment options are urgently&#xD;
      required.&#xD;
&#xD;
      Angiogenesis is a process that results in the formation of new blood vessels. Similar to&#xD;
      normal tissues, solid tumours require new blood vessels for growth and survival. Hence, drugs&#xD;
      targeting angiogenesis may be useful treatment options for patients with bowel cancer.&#xD;
&#xD;
      AMG386 and bevacizumab act on 2 different pathways relevant to angiogenesis. There is&#xD;
      evidence from laboratory and animal studies to suggest that such a combination could be&#xD;
      useful as a cancer treatment. Previous studies in humans have shown that AMG386 and&#xD;
      bevacizumab can be combined safely.. This study aims to evaluate the effectiveness and safety&#xD;
      of the combination of AMG386 and bevacizumab in patients with advanced bowel cancer.&#xD;
&#xD;
      40 patients from approximately four hospitals in Australia will participate in this trial,&#xD;
      with approximately 20 patients being enrolled at Austin Health. All participants will receive&#xD;
      the same treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control (ie non progression) at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG386 and bevacizumab</intervention_name>
    <description>AMG386 10mg/kg qw iv Bevacizumab 7.5mg/kg q3w iv</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        i) Histological diagnosis of colorectal cancer ii) Metastatic disease that is not&#xD;
        resectable iii) Age &gt; 18 years iv) Any patient in whom the investigator considers immediate&#xD;
        cytotoxic chemotherapy is not required.&#xD;
&#xD;
        v) Measurable and/or non-measurable disease as assessed by CT scan vi) ECOG performance&#xD;
        status 0, 1 or 2. vii) No prior chemotherapy except for adjuvant chemotherapy. viii)&#xD;
        Adequate bone marrow function with platelets &gt; 100 X 109/l; neutrophils &gt; 1.5 X 109/l ix)&#xD;
        Adequate renal function, with calculated creatinine clearance &gt;40 ml/min (Cockcroft and&#xD;
        Gault).&#xD;
&#xD;
        x) Adequate hepatic function with serum total bilirubin &lt; 1.5 X upper limit of normal range&#xD;
        xi) Life expectancy of at least 12 weeks xii) No other concurrent uncontrolled medical&#xD;
        conditions xiii) No other malignant disease apart from non-melanotic skin cancer or&#xD;
        carcinoma in situ of the uterine cervix or any other cancer treated with curative intent &gt;2&#xD;
        years previously without evidence of relapse xiv) Women and partners of women of&#xD;
        childbearing potential must agree to use adequate contraception xv) Written informed&#xD;
        consent including consent for biomarker studies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        i) Medical or psychiatric conditions that compromise the patient's ability to give informed&#xD;
        consent or to complete the protocol ii) Uncontrolled hypertension iii) Prior treatment with&#xD;
        VEGF inhibitors or angiopoietin inhibitors iv) Active bleeding disorders within the last 6&#xD;
        months v) Participation in any investigational drug study within the previous 4 weeks vi)&#xD;
        Patients with uncontrolled clinically significant cardiac disease, arrhythmias or angina&#xD;
        pectoris vii) Patients with a history of arterial or venous thrombosis within the last 12&#xD;
        months viii) Concurrent or prior (within 1 week before enrollment) anticoagulation therapy.&#xD;
        The concurrent use of low molecular weight heparin or low dose warfarin (ie, 1 mg daily)&#xD;
        for prophylaxis against thrombosis is acceptable while on study ix) Regular use of aspirin&#xD;
        (&gt;325mg/day) or NSAIDs (low dose aspirin (&lt;325 mg/d), or occasional use of NSAIDs is&#xD;
        acceptable) x) Treatment with immune modulators such as cyclosporine or tacrolimus within&#xD;
        the previous 4 weeks xi) CNS metastases xii) Major surgical procedure within the last 28&#xD;
        days xiii) Minor surgical procedure, placement of access device, or fine needle aspiration&#xD;
        within the last 7 days xiv) Serious non-healing wound, ulcer or bone fracture xv) 24 hour&#xD;
        urinary protein &gt; 1g/ 24 hours ( performed if urine dipstick &gt; 1+ ) xvi) Pregnancy or&#xD;
        lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niall Tebbutt</last_name>
    <role>Study Chair</role>
    <affiliation>Austin Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Effie Skrinos</last_name>
    <phone>+61394963576</phone>
    <email>effie.skrinos@austin.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Effie Skrinos</last_name>
      <phone>+61394963576</phone>
      <email>effie.skrinos@austin.org.au</email>
    </contact>
    <investigator>
      <last_name>Niall Tebbutt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <last_update_submitted>November 29, 2010</last_update_submitted>
  <last_update_submitted_qc>November 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Niall Tebbutt</name_title>
    <organization>Austin Health</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Trebananib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

